Evaluating appetite/satiety hormones and eating behaviours as predictors of weight loss maintenance with GLP‐1RA therapy in adolescents with severe obesity
Authors' conclusion
Prior to exenatide, lower leptin response to meals was associated with improved WLM with exenatide compared to placebo. The mostly null findings of this study suggest that GLP1-RA treatment may produce similar WLM for adolescents with obesity regardless of age, BMI, sex and eating behaviours.
Study context
- Population
- Adolescents with severe obesity who had ≥5% body mass index (BMI) reduction with meal replacement therapy; mean age 16.0 years, 47% female
- Participants
- 66 adolescents
- Comparison
- Once-weekly exenatide extended release vs placebo
- Primary endpoint
- Percent change in BMI from randomization to 52 weeks (primary measure of WLM)
- Follow-up
- 52 weeks
Primary result
As reported in the abstract
Lower leptin response to meal testing as predictor of WLM (BMI percent change), exenatide vs placebo
- No other significant predictors of weight loss maintenance (WLM)
- Exenatide vs Placebo: P = 0.007
- Adjusted for sex, age and BMI
Original publication
Evaluating appetite/satiety hormones and eating behaviours as predictors of weight loss maintenance with GLP‐1RA therapy in adolescents with severe obesity. Pediatr Obes. Published 9 February 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →